drugset

drugset / Trial / NCT00525798

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

NCT00525798 ↗

Phase 3 Completed 4665 enrolled Nordic Bioscience A/S Novartis · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoporosis

Timeline

Start: 2007-03
Primary completion: 2011-08
Completion: 2011-11

Publications

Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA. Oral salmon calcitonin--pharmacology in osteoporosis. Expert Opin Biol Ther. 2010 Nov;10(11):1617-29. doi: 10.1517/14712598.2010.526104. Epub 2010 Oct 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	salmon calcitonin	Unknown	0.8 mg	Oral

Indications